$ALLR Balance Sheet | Understand Stock

$ALLR

$0.92 +$0.00 (0.54%) Close

$ALLR Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Balance Sheets (Current Period Unaudited)

In millions of USD, except per-share amounts

	Q2 FY2026 As of Jun 30, 2026	Q1 FY2026 As of Mar 31, 2026	Q4 FY2025 As of Dec 31, 2025	Q3 FY2025 As of Sep 30, 2025	Q2 FY2025 As of Jun 30, 2025	Q1 FY2025 As of Mar 31, 2025	Q4 FY2024 As of Dec 31, 2024	Q3 FY2024 As of Sep 30, 2024	Q2 FY2024 As of Jun 30, 2024	Q1 FY2024 As of Mar 31, 2024	Q4 FY2023 As of Dec 31, 2023	Q3 FY2023 As of Sep 30, 2023	Q2 FY2023 As of Jun 30, 2023	Q1 FY2023 As of Mar 31, 2023	Q4 FY2022 As of Dec 31, 2022	Q3 FY2022 As of Sep 30, 2022	Q2 FY2022 As of Jun 30, 2022	Q1 FY2022 As of Mar 31, 2022	Q4 FY2021 As of Dec 31, 2021	Q3 FY2021 As of Sep 30, 2021
Current assets
Cash
Cash and cash equivalents
Receivables from ATM sales
Restricted cash
Other current assets
Prepaid expenses
Investment in Lantern Pharma Inc. stock
Tax credit receivable
Total current assets

Non-current assets:
Investment in Lantern Pharma Inc. stock
Property, plant and equipment, net
Operating lease assets
Operating lease right of use assets
Intangible assets
Total assets

Current liabilities
Accounts payable
Accrued expenses and other current liabilities
Warrant liability
Income taxes payable
Convertible debt and accrued interest, net of debt discount
Promissory note, net of discounts and accrued interest
Derivative liability
Promissory note
Convertible promissory notes and accrued interest
Secured promissory notes
Operating lease liabilities, current
Total current liabilities

Derivative liabilities
Series A Preferred Stock
Total derivative liabilities

Operating lease liabilities, net of current portion
Convertible promissory note and accrued interest, net of debt discount
Deferred tax
Total liabilities
Convertible Preferred stock value
Series A Preferred Stock
Series B Preferred Stock
Series C Convertible Preferred stock
Total convertible Preferred stock value
Redeemable preferred stock value
Series A Preferred Stock
Series B Preferred Stock
Total redeemable preferred stock value
Total redeemable preferred stock
Stockholders’ equity
Series A Preferred stock, $0.0001 par value, 500,000 authorized, 20,000 designated Series A shares, 0 and 1,417 shares issued and outstanding at December 31, 2024 and 2023, respectively (liquidation preference of $17.54 at December 31, 2023)
Common stock, $0.0001 par value: 250,000,000 shares authorized; 19,124,363 and 19,030,619 shares issued and 15,910,724 and 16,080,980 outstanding at June 30, 2026 and December 31, 2025, respectively
Additional paid-in capital
Accumulated other comprehensive loss
Accumulated deficit
Treasury stock, at cost; 3,213,639 and 2,949,639 shares at June 30, 2026, and December 31, 2025, respectively
Total stockholders’ equity
Total liabilities and stockholders’ equity

Comments